Sanofi has entered into a definitive agreement to acquire Principia Biopharma Inc., a late-stage biopharma company focused on immune-mediated diseases, in a transaction valued at approximately $3.36 billion. Principia’s Bruton tyrosine kinase (BTK) inhibitors add to Sanofi’s efforts to accelerate a portfolio of next gen transformative treatments for autoimmune diseases. BTK is present in the signaling pathways of key innate and adaptive cell types of the immune system. Being able...